Urothelial Cancer Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Urothelial Cancer Drugs Market has been segmented by Treatment (Chemotherapy and Immunotherapy) and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Urothelial Cancer Drugs Market Size

Urothelial Cancer Drugs Market Summary

Urothelial Cancer Drugs Market Analysis

The Global Urothelial Cancer Drugs Market is expected to register a CAGR of 15.5% during the forecast period.

The emergence of COVID-19 had a profound impact on the urothelial cancer drugs market. For instance, according to a study published in June 2022, titled "The Impact of the COVID-19 Pandemic on Bladder Cancer Care in the Netherlands," the number of bladder cancer (BC) diagnoses fell by 14% during the first COVID-19 wave but rose back to pre-COVID-19 levels by the end of 2020 (600 diagnoses a month). Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. Additionally, as per the May 2022 updates from the American Urological Association, during the peak of the COVID-19 pandemic in 2020, more than a quarter of patients with bladder cancer experienced care delays in the United States. As a result of the pandemic, the urothelial cancer drug market and also diagnostics had been significantly impacted. However, due to the increasing number of cancer cases, there will be continuing demand for urothelial cancer drugs.

The urothelial cancer drug market may witness rapid growth also due to the increasing awareness about bladder diseases and available therapies, healthcare expenditure, and the growing burden of bladder cancer. For instance, in March 2022, the 'Don't Go Red' theme for Bladder Cancer Awareness has been declared by the World Bladder Cancer Patient Coalition to raise awareness of warning signs and symptoms, as early detection is critical for enhancing long-term survival and quality of life.

Additionally, the increasing prevalence of bladder cancer across the world supports the market expansion over the forest period. For instance, according to the American Cancer Society, in January 2023, it was estimated that about 82,300 cases of bladder cancer would be reported in the United States, of which 62,400 will be men and 19,900 will be women. Thereby, a high number of bladder cancer cases is going to elevate the need for urothelial cancer drugs. However, side effects associated with drugs are likely to impede market growth.

Urothelial Cancer Drugs Industry Overview

The urothelial cancer drug market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known, including Merck & Co. Inc., F Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, and Novartis AG, among others.

Urothelial Cancer Drugs Market Leaders

  1. Merck & Co. Inc.

  2. Bristol-Myers Squibb Company

  3. Novartis AG

  4. F Hoffmann-La Roche AG

  5. AstraZeneca PLC

  6. *Disclaimer: Major Players sorted in no particular order
Urothelial Cancer Drugs Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Urothelial Cancer Drugs Market News

  • December 2022: Asieris stated that Hexvix, a drug used for bladder cancer diagnosis, completed dosing for the first patient in its real-world clinical study at Hainan General Hospital Lecheng Branch.
  • December 2022: Astellas, Seagen, and Merck stated that they had received FDA acceptance of sBLA for PADCEV (enfortumab vedotin-ejfv), with keytruda (pembrolizumab) for the first-line treatment of certain patients with locally advanced or metastatic urothelial cancer.

Urothelial Cancer Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Emergence and Priority of Targeted Therapy Among Biopharmaceutical Companies
    • 4.2.2 Growing Burden of Urothelial Cancer
    • 4.2.3 Increasing Awareness on Bladder Diseases and Available Therapies
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Drugs
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Treatment
    • 5.1.1 Chemotherapy
    • 5.1.2 Immunotherapy
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co. Inc.
    • 6.1.2 F Hoffmann-La Roche AG
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 AstraZeneca PLC
    • 6.1.5 Novartis AG
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Sanofi SA
    • 6.1.8 Eisai Co. Ltd.
    • 6.1.9 Astellas Pharma
    • 6.1.10 UroGen Pharma
    • 6.1.11 Pfizer Inc.
    • 6.1.12 Genentech USA Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Urothelial Cancer Drugs Industry Segmentation

As per the scope of the report, urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous bladder tumor that spreads to other parts of the body. The urothelium comprises the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. The Urothelial Cancer Drugs Market has been Segmented by Treatment (Chemotherapy and Immunotherapy) and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Treatment Chemotherapy
Immunotherapy
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Treatment
Chemotherapy
Immunotherapy
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Urothelial Cancer Drugs Market Research FAQs

What is the current Global Urothelial Cancer Drugs Market size?

The Global Urothelial Cancer Drugs Market is projected to register a CAGR of 15.5% during the forecast period (2025-2030)

Who are the key players in Global Urothelial Cancer Drugs Market?

Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, F Hoffmann-La Roche AG and AstraZeneca PLC are the major companies operating in the Global Urothelial Cancer Drugs Market.

Which is the fastest growing region in Global Urothelial Cancer Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Urothelial Cancer Drugs Market?

In 2025, the North America accounts for the largest market share in Global Urothelial Cancer Drugs Market.

What years does this Global Urothelial Cancer Drugs Market cover?

The report covers the Global Urothelial Cancer Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Urothelial Cancer Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Urothelial Cancer Drugs Industry Report

Statistics for the 2025 Global Urothelial Cancer Drugs market share, size and revenue growth rate, created by Mordor Intelligenceā„¢ Industry Reports. Global Urothelial Cancer Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Global Urothelial Cancer Drugs Report Snapshots

Access Report long-arrow-right